About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Panzhihua Steel (Pangang) has implemented a self-developed short-process high‑purity vanadium pentoxide (V2O5) production technology that addresses the trade-off between high product quality and low-cost manufacturing. Since April the method has been

2026-09-14

Panzhihua Steel (Pangang) has implemented a self-developed short-process high‑purity vanadium pentoxide (V2O5) production technology that addresses the trade-off between high product quality and low-cost manufacturing. Since April the method has been used on the high‑purity vanadium line at Panzhihua Vanadium Products Co., sharply reducing impurity levels and cutting material consumption costs by more than 15% versus before the upgrade.

Other News
2026-09-14

ECB Governing Council member Kassacs: The possibility of further policy tightening is increasing, and we can take action gradually without rushing.

ECB Governing Council member Kassacs: The possibility of further policy tightening is increasing, and we can take action gradually without rushing.
2026-09-14

At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, mo

At its Sept. 14, 2026 interim results briefing, Junshi Biosciences said JS203 (CD20/CD3 bispecific) is expected to initiate Phase III trials in 2026. JS207 (PD-1/VEGF bispecific) is in Phase II and is being tested in combination with chemotherapy, monoclonal antibodies and ADCs across multiple tumor types; Junshi plans to start Phase III for JS207 in 2026.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.